Arizona Legislature to Examine Obesity as Chronic Disease, GLP-1 Coverage Costs
Legislators Form Committee to Tackle Policies on Obesity & GLP-1 Coverage
Arizona lawmakers created an advisory committee examining whether to recognize obesity as a chronic disease and to analyze the financial impact of covering preventative treatments through the state's Medicaid program.
The bipartisan legislative panel, chaired by Senator David Gowan (R-Sierra Vista), approved the formation of the committee, which will deliver a comprehensive report to the Arizona State Legislature on obesity-related healthcare costs and potential preventative care interventions.
The panel explored expanding Arizona Health Care Cost Containment System (AHCCCS) coverage for GLP-1 weight loss medications but opted to refer the coverage decision to the newly formed advisory committee for further analysis.
An AHCCCS representative reported the agency currently spends approximately $73 million annually on GLP-1 medications, with $13 million coming from the state general fund. Recent federal price reductions for certain GLP-1 drugs are projected to decrease AHCCCS spending to $23 million overall and $5 million in state expenditures.
AHCCCS noted that six of 14 states previously covering GLP-1s for obesity treatment have discontinued coverage due to higher-than-anticipated utilization costs. The advisory committee will examine these coverage patterns and cost implications as part of its recommendations to Arizona legislators.
The committee's findings will inform potential policy changes regarding obesity treatment coverage and preventative care investments in Arizona's healthcare system.
Information in this article was sourced from KJZZ.






